204 related articles for article (PubMed ID: 15562829)
1. Genetic blockade of the insulin-like growth factor 1 receptor for human malignancy.
Adachi Y; Lee CT; Carbone DP
Novartis Found Symp; 2004; 262():177-89; discussion 190-2, 265-8. PubMed ID: 15562829
[TBL] [Abstract][Full Text] [Related]
2. Genetic blockade of the insulin-like growth factor-I receptor: a promising strategy for human pancreatic cancer.
Min Y; Adachi Y; Yamamoto H; Ito H; Itoh F; Lee CT; Nadaf S; Carbone DP; Imai K
Cancer Res; 2003 Oct; 63(19):6432-41. PubMed ID: 14559833
[TBL] [Abstract][Full Text] [Related]
3. Growth factor receptors as therapeutic targets: strategies to inhibit the insulin-like growth factor I receptor.
Surmacz E
Oncogene; 2003 Sep; 22(42):6589-97. PubMed ID: 14528284
[TBL] [Abstract][Full Text] [Related]
4. Insulin-like growth factor I receptor blockade enhances chemotherapy and radiation responses and inhibits tumour growth in human gastric cancer xenografts.
Min Y; Adachi Y; Yamamoto H; Imsumran A; Arimura Y; Endo T; Hinoda Y; Lee CT; Nadaf S; Carbone DP; Imai K
Gut; 2005 May; 54(5):591-600. PubMed ID: 15831900
[TBL] [Abstract][Full Text] [Related]
5. The IGF receptor as anticancer treatment target.
Macaulay VM
Novartis Found Symp; 2004; 262():235-43; discussion 243-6, 265-8. PubMed ID: 15562833
[TBL] [Abstract][Full Text] [Related]
6. Insulin-like growth factor-I receptor blockade reduces the invasiveness of gastrointestinal cancers via blocking production of matrilysin.
Adachi Y; Li R; Yamamoto H; Min Y; Piao W; Wang Y; Imsumran A; Li H; Arimura Y; Lee CT; Imai K; Carbone DP; Shinomura Y
Carcinogenesis; 2009 Aug; 30(8):1305-13. PubMed ID: 19493905
[TBL] [Abstract][Full Text] [Related]
7. Adenovirus expressing shRNA to IGF-1R enhances the chemosensitivity of lung cancer cell lines by blocking IGF-1 pathway.
Lee YJ; Imsumran A; Park MY; Kwon SY; Yoon HI; Lee JH; Yoo CG; Kim YW; Han SK; Shim YS; Piao W; Yamamoto H; Adachi Y; Carbone DP; Lee CT
Lung Cancer; 2007 Mar; 55(3):279-86. PubMed ID: 17134788
[TBL] [Abstract][Full Text] [Related]
8. Growth-inhibitory effects of human anti-insulin-like growth factor-I receptor antibody (A12) in an orthotopic nude mouse model of anaplastic thyroid carcinoma.
Wang Z; Chakravarty G; Kim S; Yazici YD; Younes MN; Jasser SA; Santillan AA; Bucana CD; El-Naggar AK; Myers JN
Clin Cancer Res; 2006 Aug; 12(15):4755-65. PubMed ID: 16899627
[TBL] [Abstract][Full Text] [Related]
9. Insulin-like growth factor-I receptor as a marker for prognosis and a therapeutic target in human esophageal squamous cell carcinoma.
Imsumran A; Adachi Y; Yamamoto H; Li R; Wang Y; Min Y; Piao W; Nosho K; Arimura Y; Shinomura Y; Hosokawa M; Lee CT; Carbone DP; Imai K
Carcinogenesis; 2007 May; 28(5):947-56. PubMed ID: 17183068
[TBL] [Abstract][Full Text] [Related]
10. Insulin-like growth factor-I receptor signaling blockade combined with radiation.
Allen GW; Saba C; Armstrong EA; Huang SM; Benavente S; Ludwig DL; Hicklin DJ; Harari PM
Cancer Res; 2007 Feb; 67(3):1155-62. PubMed ID: 17283150
[TBL] [Abstract][Full Text] [Related]
11. Recombinant adenoviruses expressing dominant negative insulin-like growth factor-I receptor demonstrate antitumor effects on lung cancer.
Lee CT; Park KH; Adachi Y; Seol JY; Yoo CG; Kim YW; Han SK; Shim YS; Coffee K; Dikov MM; Carbone DP
Cancer Gene Ther; 2003 Jan; 10(1):57-63. PubMed ID: 12489029
[TBL] [Abstract][Full Text] [Related]
12. Effects of genetic blockade of the insulin-like growth factor receptor in human colon cancer cell lines.
Adachi Y; Lee CT; Coffee K; Yamagata N; Ohm JE; Park KH; Dikov MM; Nadaf SR; Arteaga CL; Carbone DP
Gastroenterology; 2002 Oct; 123(4):1191-204. PubMed ID: 12360481
[TBL] [Abstract][Full Text] [Related]
13. Selective inhibition of SCLC growth by the A12 anti-IGF-1R monoclonal antibody correlates with inhibition of Akt.
Yeh J; Litz J; Hauck P; Ludwig DL; Krystal GW
Lung Cancer; 2008 May; 60(2):166-74. PubMed ID: 18006183
[TBL] [Abstract][Full Text] [Related]
14. Insulin-like growth factor-1 receptor acts as a growth regulator in synovial sarcoma.
Friedrichs N; Küchler J; Endl E; Koch A; Czerwitzki J; Wurst P; Metzger D; Schulte JH; Holst MI; Heukamp LC; Larsson O; Tanaka S; Kawai A; Wardelmann E; Buettner R; Pietsch T; Hartmann W
J Pathol; 2008 Dec; 216(4):428-39. PubMed ID: 18855347
[TBL] [Abstract][Full Text] [Related]
15. Treatment of hematologic malignancies and solid tumors by inhibiting IGF receptor signaling.
Mitsiades CS; Mitsiades N
Expert Rev Anticancer Ther; 2005 Jun; 5(3):487-99. PubMed ID: 16001956
[TBL] [Abstract][Full Text] [Related]
16. Control of apoptosis in human multiple myeloma by insulin-like growth factor I (IGF-I).
Jernberg-Wiklund H; Nilsson K
Adv Cancer Res; 2007; 97():139-65. PubMed ID: 17419944
[TBL] [Abstract][Full Text] [Related]
17. Plasma and tissue insulin-like growth factor-I receptor (IGF-IR) as a prognostic marker for prostate cancer and anti-IGF-IR agents as novel therapeutic strategy for refractory cases: a review.
Ozkan EE
Mol Cell Endocrinol; 2011 Sep; 344(1-2):1-24. PubMed ID: 21782884
[TBL] [Abstract][Full Text] [Related]
18. Combination therapy with conditionally replicating adenovirus and replication defective adenovirus.
Lee CT; Park KH; Yanagisawa K; Adachi Y; Ohm JE; Nadaf S; Dikov MM; Curiel DT; Carbone DP
Cancer Res; 2004 Sep; 64(18):6660-5. PubMed ID: 15374981
[TBL] [Abstract][Full Text] [Related]
19. Luteolin inhibits insulin-like growth factor 1 receptor signaling in prostate cancer cells.
Fang J; Zhou Q; Shi XL; Jiang BH
Carcinogenesis; 2007 Mar; 28(3):713-23. PubMed ID: 17065200
[TBL] [Abstract][Full Text] [Related]
20. Comparison of three approaches for inhibiting insulin-like growth factor I receptor and their effects on NSCLC cell lines in vitro.
Cosaceanu D; Carapancea M; Alexandru O; Budiu R; Martinsson HS; Starborg M; Vrabete M; Kanter L; Lewensohn R; Dricu A
Growth Factors; 2007 Feb; 25(1):1-8. PubMed ID: 17454144
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
